Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials

Published:2023-11 Issue: Volume:120 Page:102623
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Iannantuono Giovanni Maria,Chandran Elias,Floudas Charalampos S.,Choo-Wosoba Hyoyoung,Butera Gisela,Roselli Mario,Gulley James L.,Karzai Fatima

Funder

National Institutes of Health

National Cancer Institute

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference77 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019

5. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer;Smith;N Engl J Med,2022

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian;Cancers;2024-06-26

2. Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer;American Journal of Clinical Oncology;2024-06-20

3. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis;BMC Cancer;2024-06-08

4. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis;Clinical and Translational Oncology;2024-05-15

5. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review;European Urology Oncology;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3